ICLR Stock Forecast: ICON plc Price Predictions for 2026-2027
The 18 Wall Street analysts covering ICON plc hold a median 12-month price target of $230 — +23.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 75 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores ICON plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (47): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ICLR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ICLR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.2% from it.
Of the 20 most recent actions, 18 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Baird | Maintains | Outperform | $210 → $249 |
| 29 Oct 2026 | Barclays | Maintains | Equal-Weight | $175 → $230 |
| 29 Oct 2026 | Citigroup | Maintains | Neutral | $175 → $215 |
| 29 Oct 2026 | RBC Capital | Maintains | Outperform | $185 → $226 |
| 29 Oct 2026 | TD Cowen | Maintains | Buy | $197 → $254 |
| 29 Oct 2026 | Truist Securities | Maintains | Buy | $209 → $268 |
| 29 Oct 2026 | UBS | Maintains | Neutral | $195 → $236 |
| 30 Sept 2026 | UBS | Reinstates | Neutral | $195 |
| 18 Sept 2026 | Citigroup | Maintains | Neutral | $180 → $175 |
| 31 July 2026 | Citigroup | Maintains | Neutral | $165 → $180 |
| 31 July 2026 | Truist Securities | Reiterates | Buy | $207 → $209 |
| 30 June 2026 | Truist Securities | Upgrade | Buy | $159 → $207 |
| 26 June 2026 | Mizuho | Maintains | Outperform | $180 → $190 |
| 25 June 2026 | B of A Securities | Maintains | Underperform | $125 → $150 |
| 25 June 2026 | Baird | Maintains | Outperform | $168 → $186 |
| 25 June 2026 | Barclays | Maintains | Equal-Weight | $160 → $175 |
| 25 June 2026 | BMO Capital | Maintains | Outperform | $160 → $187 |
| 25 June 2026 | Citigroup | Maintains | Neutral | $140 → $165 |
| 25 June 2026 | Evercore ISI Group | Maintains | Outperform | $150 → $180 |
| 25 June 2026 | JP Morgan | Maintains | Neutral | $130 → $155 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ICLR.
This page is one stock. Monday covers all of them.
ICLR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ICLR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, ICON plc returned +18.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ICLR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 78.0×
- Price / sales
- 1.8×
- Price / book
- 1.6×
- EV / EBITDA
- 36.1×
Cheaper than 10% of US stocks
Cheaper than 51% of US stocks
Cheaper than 52% of US stocks
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 23.2%
- Operating margin
- 2.7%
- Net margin
- —
Higher than 25% of US stocks
Higher than 48% of US stocks
- Return on equity
- 4.7%
- Return on assets
- 0.9%
- Dividend yield
- —
Higher than 52% of US stocks
Higher than 47% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ICON plc has a market value of $14.6B and an enterprise value of $17.3B.
Revenue in the twelve months to 30 June 2026: $8.4B. The latest quarter grew 2.3% year on year.
Net income over the same four quarters: −$217.0M, a −2.6% net margin.
Diluted earnings per share, trailing twelve months: $0.56.
Free cash flow in the twelve months to 30 June 2026: $436.0M.
ICON plc spent $250.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 78.0×; forward P/E: 16.8× — the forward figure prices analyst consensus estimates, not reported earnings.
ICON plc employs 40,250 people — $208K of revenue per employee.
Data provided by Twelve Data
ICLR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ICLR’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own ICON plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ICLR
What is the ICLR stock price forecast for 2026-2027?
The 18 Wall Street analysts covering ICON plc have a median 12-month price target of $230, with estimates ranging from $180 to $268. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ICLR stock a buy right now?
Of the 18 analysts covering ICON plc, 10 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ICON plc 75 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ICLR?
As at 21 Nov 2026, ICON plc ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).
Will ICLR stock go up?
No one can know that. What the data says: the median 12-month target from 18 analysts implies +23.2% from the last close, and Ticker Nerd's factor model ranks ICON plc 75 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ICLR stock forecast for 2030?
No analyst covering ICON plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICLR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $180 to $268 over the next 12 months.
How has ICLR stock performed over the past year?
ICON plc returned +18.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ICON plc do?
ICON plc is a clinical research organisation that provides outsourced drug and device development services to pharmaceutical, biotechnology, medical device, and public health customers. The company supports clinical development across the full product lifecycle, including study design, trial management, data solutions, site and patient access, laboratory services, and commercialization support.
About ICON plc.
ICON plc is a clinical research organisation that provides outsourced drug and device development services to pharmaceutical, biotechnology, medical device, and public health customers. The company supports clinical development across the full product lifecycle, including study design, trial management, data solutions, site and patient access, laboratory services, and commercialization support. ICON plc also offers consulting and advisory capabilities, decentralized and hybrid trial services, real-world intelligence, and therapeutic expertise across areas such as oncology, cardiology, infectious disease, immunology, and central nervous system disorders. Its work is used to help clients run clinical programs more efficiently and bring medical treatments through development and approval pathways. Headquartered in Dublin, Ireland, ICON plc operates through a broad international network and serves organizations in multiple global markets.
CEO Mr. Barry Balfe · 40,250 employees · Ireland · https://www.iconplc.com